Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Mylan | Bevacizumab | Abevmy |  | 2021-04-21 |  |  |
Bevacizumab | Lextemy |  |  |  |  | |
GSK | Niraparib | Zejula | 2027-08-12 | 2017-03-27 |  |  |
Roche | Bevacizumab | Avastin |  | 2005-01-12 | $1,987.484 M | Q4/22-Q3/23 |
Pfizer | Bevacizumab | Zirabev |  | 2019-06-27 | $424 M | Y2023 |
Amneal Pharmaceuticals | Bevacizumab | Alymsys |  | 2022-04-13 |  |  |
Celltrion | Bevacizumab | Vegzelma |  | 2022-09-27 |  |  |
Genentech | Bevacizumab | Avastin |  | 2004-02-26 |  |  |
Amgen | Bevacizumab | Mvasi |  | 2017-09-14 |  |  |
Stada Arzneimittel | Bevacizumab | Oyavas |  | 2021-03-26 |  |  |
Samsung Bioepis | Bevacizumab | Aybintio |  | 2020-08-19 |  |  |
Bevacizumab | Onbevzi |  | 2021-01-11 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|